GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), of the National Institutes of Health (NIH), to support the Company’s efforts to develop novel adenovector-based vaccines for HSV-2, the virus responsible for most cases of genital herpes. The SBIR grant, valued at $600,000 over 2 years, will support work being conducted at GenVec, the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center and the University of Washington by Drs. Lawrence Corey, Greg Mahairas, and David Koelle.
